title: Molecular considerations for development of phage antibody libraries.
abstract: Nowadays, phage display libraries are used as robust tools for discovery and evolution of peptide/protein based drugs as well as targeting molecules, in particular monoclonal antibodies (mAbs) and its fragments (i.e., scFvs, Fabs, or bivalent F(ab')₂). Phage display technology, as a molecular diversity approach, enables selection of antibody fragments (e.g., scFv/Fab) with high affinity, specificity and effector functions against various targets. However, such selection process itself is largely dependent upon various molecular factors such as methods for construction of phage library, phage/phagemid vectors, helper phage, host cells and biopanning processes. The current review article provides important molecular considerations for successful development of phage antibody libraries that may be used as a platform for translation of antibody fragments into viable diagnostic/therapeutic reagents.
authors.affiliation: Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Tohidkia
authors.forename: Jaleh
authors.initials: J
authors.lastname: Barar
authors.forename: Farzad
authors.initials: F
authors.lastname: Asadi
authors.forename: Yadollah
authors.initials: Y
authors.lastname: Omidi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000235:genetics; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000235:genetics; D001435:Bacteriophages / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D019151:Peptide Library; D011994:Recombinant Proteins / Q000096:biosynthesis; D013678:Technology, Pharmaceutical / Q000639:trends; D014765:Viral Vaccines / Q000276:immunology; D014773:Virology / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D019151:Peptide Library; D011994:Recombinant Proteins; D014765:Viral Vaccines